Asset
ANASTROZOLE
Revenue
No revenue reported in loaded filings.
Clinical trials (32)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00300508 | phase3 | completed | 1996-01-01 | — | AstraZeneca | 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer |
| NCT04556773 | phase1 | active_not_recruiting | 2020-12-17 | 2023-08-16 | AstraZeneca | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer |
| NCT00544986 | phase4 | completed | 2005-06-01 | 2007-11-01 | AstraZeneca | A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer |
| NCT00291759 | phase3 | completed | 1996-01-01 | 2009-06-01 | AstraZeneca | ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation. |
| NCT00784940 | phase3 | completed | 1998-06-01 | 2005-03-01 | AstraZeneca | ATAC - Bone Density Sub-Protocol |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 020541 | NDA | ANI PHARMACEUTICALS INC |
Marketed products (1)
- ARIMIDEX